Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Eli Lilly And Co before investing.

In this article, we go over a few key elements for understanding Eli Lilly And Co’s stock price such as:

• Eli Lilly And Co’s current stock price and volume
• Why Eli Lilly And Co’s stock price changed recently
• Upgrades and downgrades for LLY from analysts
• LLY’s stock price momentum as measured by its relative strength

About Eli Lilly And Co (LLY)

Before we jump into Eli Lilly And Co’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Eli Lilly and Company is engaged in drug manufacturing businesses. It discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, and others. Its immunology products include Olumiant, Taltz, oral IL-17 inhibitors and others. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab and Forteo. It maintains special business groups for service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in over 110 countries.

Want to learn more about Eli Lilly And Co’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Eli Lilly And Co.

Eli Lilly And Co’s Stock Price as of Market Close

As of October 06, 2023, 4:00 PM, CST, Eli Lilly And Co’s stock price was $565.22.

Eli Lilly And Co is up 4.38% from its previous closing price of $541.48.

During the last market session, Eli Lilly And Co’s stock traded between $531.61 and $542.50. Currently, there are 899.70 million shares of Eli Lilly And Co stock available for purchase.

Eli Lilly And Co’s price-earnings (P/E) ratio is currently at 75.2, which is high compared to the Pharmaceuticals industry median of 18.7. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Eli Lilly And Co Stock Price History

Eli Lilly And Co’s (LLY) price is currently up 5.23% so far this month.

During the month of October, Eli Lilly And Co’s stock price has reached a high of $566.36 and a low of $516.57.

Over the last year, Eli Lilly And Co has hit prices as high as $601.84 and as low as $302.14. Year to date, Eli Lilly And Co’s stock is up 104.63%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Eli Lilly And Co Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of October 05, 2023, there were 0 analysts who downgraded Eli Lilly And Co’s stock and 3 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Eli Lilly And Co’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Eli Lilly And Co’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Eli Lilly And Co’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Eli Lilly And Co (LLY) by visiting AAII Stock Evaluator.

Relative Price Strength of Eli Lilly And Co

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of October 05, 2023, Eli Lilly And Co has a weighted four-quarter relative price strength of 12.95%, which translates to a Momentum Score of 92 and is considered to be Very Strong.

Want to learn more about how Eli Lilly And Co is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Eli Lilly And Co Stock Price: Bottom Line

As of October 6, 2023, Eli Lilly And Co’s stock price is $565.22, which is up 4.38% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Eli Lilly And Co stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.